Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases (Q37231972)

19 August 2017

Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases (English)

1 reference

Leticia Quintanilla-Martinez

19 August 2017

22

object named as

Leticia Quintanilla-Martinez

0 references

Dirk Schadendorf

19

object named as

Dirk Schadendorf

1 reference

19 August 2017

11

Keith Flaherty

1 reference

19 August 2017

10

Ghazaleh Tabatabai

1 reference

19 August 2017

7

Reinhard Dummer

1 reference

19 August 2017

21

Dagmar Kulms

1 reference

19 August 2017

17

Benjamin Weide

1 reference

19 August 2017

20

Claus Garbe

1 reference

19 August 2017

1

Heike Niessner

1 reference

19 August 2017

12

Tobias Sinnberg

1 reference

19 August 2017

23

Friedegund Meier

1 reference

19 August 2017

Andrea Forschner

2

1 reference

19 August 2017

Bernhard Klumpp

3

1 reference

19 August 2017

Jürgen B Honegger

4

1 reference

19 August 2017

Maria Witte

5

1 reference

19 August 2017

Antje Bornemann

6

1 reference

19 August 2017

Annemarie Adam

8

1 reference

19 August 2017

Jürgen Bauer

9

1 reference

19 August 2017

Daniela Beck

13

1 reference

19 August 2017

Ulrike Leiter

14

1 reference

19 August 2017

Cornelia Mauch

15

1 reference

19 August 2017

Alexander Roesch

16

1 reference

19 August 2017

Thomas Eigentler

18

1 reference

19 August 2017

language of work or name

English

0 references

publication date

3 February 2013

1 reference

19 August 2017

1 reference

19 August 2017

2

1 reference

19 August 2017

1

1 reference

19 August 2017

76-85

1 reference

Tumor microenvironment in the brain

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797558

Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032)

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797558

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797558

Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797558

Multimodality treatment of brain metastases: an institutional survival analysis of 275 patients

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797558

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797558

Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797558

The role of the organ microenvironment in brain metastasis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797558

Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797558

Determinants of survival in patients with brain metastases from cutaneous melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797558

Final version of 2009 AJCC melanoma staging and classification

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797558

The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797558

Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797558

The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797558

Deregulated Akt3 activity promotes development of malignant melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797558

Mutations of the BRAF gene in human cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797558

Human melanoma progression in skin reconstructs : biological significance of bFGF.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797558

Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797558

Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797558

Astrocyte-derived cytokines contribute to the metastatic brain specificity of breast cancer cells

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797558

Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797558

Growth and phenotypic characteristics of human nevus cells in culture

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797558

Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797558

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797558

3 September 2018

Identifiers

DOI

10.1002/CAM4.50

1 reference

19 August 2017

1 reference

19 August 2017

1 reference